Navigation Links
Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders. The drug candidate is a novel oral compound intended for the treatment of a common psychiatric disorder.

"We are very happy to see our long-standing partner, Taisho, effectively continue its efforts under our existing collaboration. We look forward to the Phase 1 results and the continued progress of this program," stated Jack Lief, Arena's President and Chief Executive Officer.

Under an amended agreement with Taisho, which was initially executed in May of 2000 to research a number of different GPCR targets of interest to Taisho, Taisho is responsible for development and commercialization of the drug candidate. Arena is entitled to a low single digit royalty on any product revenues received by Taisho from the sale of the drug candidate. If Taisho out-licenses the drug candidate, Arena is entitled to receive additional payments after Taisho recovers expenses associated with the research and development of the GPCR-focused projects. Arena is not entitled to any further milestone payments under the partnership.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... show promising neurological recovery in severely-...atients treated with Cethrin, HOPKINTON, Mass., M...icals, Inc. (Nasdaq: ALSE ) today announced 12-mo...al of Cethrin, a proprietary recombinant,protein t...tore motor and,sensory function after spinal cord ...
(Date:5/12/2008)...AM, Mass., May 12 /- Arbios...d today that the Company has received,approval fro... an,Investigational Device Exemption ("IDE") to be...os, extracorporeal (outside the body) liver assist...ents suffering from,chronic liver disease., "We a...
(Date:5/12/2008)...TA, May 12 /- CryoLife, Inc...d tissue processing company, today announced,the f... allograft heart,valve in a patient at the Clevela...avia, a cardiac surgeon with the Heart and Vascula...used to process the combination aortic-mitral huma...
(Date:5/12/2008)...tients in Cohort 3 Demonstrated Improvement in T-C...peutic Potential of HspE7, SAN DIEGO, May 12 /PRN...rporation (TSX: NVN) today announced positive immu...g Phase 1 clinical trial of its lead product,candi...lial neoplasia, or,CIN, a precursor to cervical ca...
Breaking Medicine Technology:Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic 2CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Full Service Community Hospitals Blast Misleading Letter to Candidates From Limited Service Hospitals 8223 1Full Service Community Hospitals Blast Misleading Letter to Candidates From Limited Service Hospitals 8223 2Full Service Community Hospitals Blast Misleading Letter to Candidates From Limited Service Hospitals 8223 3Full Service Community Hospitals Blast Misleading Letter to Candidates From Limited Service Hospitals 8223 4Full Service Community Hospitals Blast Misleading Letter to Candidates From Limited Service Hospitals 8223 5CDC Uses New Technical Approach to Enable Hospital Reporting of Healthcare Associated Infections 8221 1CDC Uses New Technical Approach to Enable Hospital Reporting of Healthcare Associated Infections 8221 2The American Veteran Targets TBI and PTSD 8219 1The American Veteran Targets TBI and PTSD 8219 2The American Veteran Targets TBI and PTSD 8219 3Claimsnet to Acquire Acceptius 8217 1Claimsnet to Acquire Acceptius 8217 2
...)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israe...ay pre-clinical data from trials of BL-1040 demons...terioration of the myocardium,after a myocardial i...latation and eventual heart failure in a pig model...feld Cardiac Research,Institute at Sheba Medical C...
...olled Study in Inoperable Chronic,Thromboembolic P...ion in Pulmonary Vascular Resistance Met - Six-Min...spnoea Score and,Biological Disease Marker , , A... (SWX:,ATLN) announced today the initial results f...ter study BENEFiT (Bosentan Effects in,Inoperable ...
Other Medicine Technology:BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:5/13/2008)... Temperature Stable Treatment for Hemophilia With ...ence to Patients, PRINCETON, N.J., May 13 /PRNews...at the US Food and Drug Administration (FDA) has a...Recombinant] Room Temperature,Stable), the first r...le,for the treatment of bleeding episodes in patie...
(Date:5/13/2008)... on electronic bingo to fulfill the unmet needs of...mmunities, SACRAMENTO, Calif., May 13 /PRNewswire...nnounced its formation to advocate for the use of,...bingo as a responsible,legal and consistent fundi...zations for this new alliance include Disabled Spo...
(Date:5/13/2008)...ration Among 52 Companies Recognized for Promoting...LE GROVE, Minn., May 13 /PRNewswire/ -- The Nation... organization of large employers, today,honored Da...t and,dedication to promoting a healthy workplace ...ees and families., (Logo: http://www.newscom.com...
(Date:5/13/2008)... rental revenue increase 12.0 percent demonstratin...l-Rom reporting for first time since separation; s...owing results, - Management updates financial guid... and operational momentum, BATESVILLE,...oldings,Inc. (NYSE: HRC ), reporting for the fir...
Breaking Medicine News(10 mins):Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Charities Form Alliance to Preserve and Improve Charity Bingo 2Health News:National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles 2Health News:National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles 3Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 2Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 3Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 4Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 5Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 6Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 7Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 8Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 9Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 10Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 11Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 12Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 13Health News:Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year 14
... research had showed that it is possible to use th...IVs //genetic makeup. This is for the first time s... part of HIV to destroy the virus in a novel HIV t...g and is often a common phenomenon in plants and a...
... study had found out that colonoscopy may be the f...ancer. For patients suspected with colorectal canc...ectal neoplasias, which are adenomas of 1cm in dia...cer. Researchers had used colonoscopy to detect pr...
...two researches presented in the annual meeting of ...ed// the importance of having low fat diet to redu...ied the recurrence or relapse of cancer in postmen...er who were given a low fat diet versus the same w...
...earchers have identified a set of cells in the pan... and cause diabetes type 1. The researchers from U...s Center says their research is likely to change t...munity and may also change the way other autoimmun...
Other Medicine News:
...stem delivers an unmatched combination of speed, a...tion for assessing and monitoring a patient's A1C ...ires only a simple fingerstick and delivers A1C re...en and time-tested having received full NGSP certi...
Metrika's A1cNow Monitor is the first ever single-use test for hemoglobin A1c, it is the "gold standard" indicator of diabetes management. The test is easy to use, needs only a drop of blood and take
The sole coagulation analyzer in the world that uses a unique dry reagent card.
...fully automated, benchtop coagulation workstation ...munological assays in true random access fashion. ...fers high throughput and rapid processing of STAT ...ing. All sample and calibrator dilutions are perfo...
Medicine Products: